全文获取类型
收费全文 | 12659篇 |
免费 | 913篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 426篇 |
妇产科学 | 233篇 |
基础医学 | 2102篇 |
口腔科学 | 293篇 |
临床医学 | 1227篇 |
内科学 | 2232篇 |
皮肤病学 | 538篇 |
神经病学 | 1439篇 |
特种医学 | 505篇 |
外科学 | 1349篇 |
综合类 | 101篇 |
一般理论 | 11篇 |
预防医学 | 931篇 |
眼科学 | 174篇 |
药学 | 849篇 |
中国医学 | 10篇 |
肿瘤学 | 1084篇 |
出版年
2023年 | 119篇 |
2022年 | 185篇 |
2021年 | 400篇 |
2020年 | 269篇 |
2019年 | 328篇 |
2018年 | 384篇 |
2017年 | 323篇 |
2016年 | 388篇 |
2015年 | 365篇 |
2014年 | 488篇 |
2013年 | 603篇 |
2012年 | 888篇 |
2011年 | 828篇 |
2010年 | 436篇 |
2009年 | 444篇 |
2008年 | 669篇 |
2007年 | 671篇 |
2006年 | 643篇 |
2005年 | 588篇 |
2004年 | 542篇 |
2003年 | 480篇 |
2002年 | 476篇 |
2001年 | 294篇 |
2000年 | 246篇 |
1999年 | 211篇 |
1998年 | 122篇 |
1997年 | 82篇 |
1996年 | 66篇 |
1995年 | 79篇 |
1994年 | 71篇 |
1993年 | 88篇 |
1992年 | 114篇 |
1991年 | 109篇 |
1990年 | 121篇 |
1989年 | 103篇 |
1988年 | 97篇 |
1987年 | 83篇 |
1986年 | 88篇 |
1985年 | 86篇 |
1984年 | 78篇 |
1983年 | 63篇 |
1982年 | 52篇 |
1981年 | 52篇 |
1980年 | 43篇 |
1979年 | 73篇 |
1978年 | 45篇 |
1977年 | 49篇 |
1974年 | 41篇 |
1973年 | 54篇 |
1968年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Collagens are the most abundant proteins in the extracellular matrix. They provide a framework to build organs and tissues and give structural support to make them resistant to mechanical load and forces. Several intra‐ and extracellular modifications are needed to make functional collagen molecules, intracellular post‐translational modifications of proline and lysine residues having key roles in this. In this article, we provide a review on the enzymes responsible for the proline and lysine modifications, that is collagen prolyl 4‐hydroxylases, 3‐hydroxylases and lysyl hydroxylases, and discuss their biological functions and involvement in diseases. 相似文献
2.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
3.
4.
5.
6.
7.
8.
9.
Decreases in sex hormone levels with menopause may bring about a number of consequences in women's general health and sexual well-being, especially when levels decline suddenly and prematurely, as in surgical menopause. In addition to the well-established role of estrogens in preserving the biological basis of sexual response, there is emerging evidence that androgens are significant independent determinants affecting sexual desire, activity and satisfaction, as well as mood, energy and other components of women's health. Hypoactive sexual desire disorder (HSDD), a persistent absence of sexual fantasies or thoughts and/or desire for and receptivity to sexual activity that causes personal distress, is experienced by some postmenopausal women. Even though conventional hormone therapy with estrogens or estrogens and progestogens may be effective for vaginal atrophy, increasing vaginal lubrication and reducing dyspareunia, it has not been shown to consistently increase sexual desire or activity and many women with sexual dysfunction remain unresponsive. Several recent, large, phase III studies have shown that the addition of transdermal testosterone to conventional hormone therapy can be helpful in surgically menopausal women presenting with HSDD. After 24 weeks of treatment in these studies, testosterone-treated women experienced significantly greater increases in satisfying sexual activity and sexual desire, and greater decreases in distress, than placebo-treated women. Accurate clinical assessment and individualized management of sexual symptoms are fundamentally important for all menopausal women with HSDD or other sexual problems. 相似文献
10.
C Schmitt J Brachmann W Saggau T Beyer B Waldecker K Scharowski T Hilbel M Montero B Offner W Sch?ls 《Zeitschrift für Kardiologie》1991,80(11):665-672
In 41 patients with recurrent sustained ventricular tachycardia and/or ventricular fibrillation an integrated pacemaker-defibrillator-system (PCD, Medtronic, model 7216 A or 7217 B) was implanted. In 21 out of 24 (88%) patients a new transvenous implantation technique in combination with a subcutaneous patch electrode was used. The implanted devices comprise antibradycardiac pacemaker functions, two different forms of antitachycardiac pacemaker functions (ramp and burst pacing), and internal cardioversion or defibrillation capabilities. During a mean follow-up of 8 months 147 episodes of ventricular tachycardia were detected, 131 of them were terminated successfully by antitachycardiac pacing; in 13 episodes internal cardioversion was applied to revert ventricular tachycardia. Twenty-seven episodes of ventricular fibrillation or rapid ventricular tachycardia (greater than 200/min) were detected and successfully terminated by internal defibrillation. In six patients with intermittent rapid atrial fibrillation, change of antiarrhythmic therapy was required to avoid activation of the device. The new integrated pacemaker-defibrillator systems improve therapy in patients with life-threatening tachyarrhythmias by reducing the number of internal cardioversions/defibrillations; the non-thoracotomy approach reduces the post operative risk. 相似文献